Trevogrumab: Regeneron's Myostatin Antibody Aims to Keep the Muscle On During GLP-1 Weight Loss (July 16, 2026)
Table of Contents
The muscle problem hiding inside the GLP-1 revolution
The GLP-1 drugs have rewritten obesity medicine, but they come with a quiet asterisk: a big chunk of the weight people lose is not fat. In Regeneron's COURAGE program, roughly a third of the weight lost on semaglutide came from lean body mass - muscle, not adipose tissue. That matters because muscle drives metabolic rate, mobility, glucose handling, and resilience in aging. Lose too much of it and you can end up lighter but weaker, with a body composition that undercuts the very health gains weight loss is supposed to deliver. The race to solve this has produced a small class of muscle-preserving add-ons, and Regeneron's contender is trevogrumab.
What trevogrumab is
Trevogrumab (REGN1033, also known by the code SAR391786) is a fully human monoclonal antibody that binds and neutralizes myostatin, also called growth differentiation factor 8 (GDF-8). Myostatin is the body's natural brake on muscle growth - block it, and muscle is freed to be preserved or built. Regeneron originally explored the antibody for age-related muscle loss (sarcopenia), but its most consequential use now is as a lean-mass-sparing partner for incretin weight-loss drugs. Conceptually it sits alongside Scholar Rock's apitegromab (which blocks the myostatin precursor), the ActRII-blocking antibody bimagrumab, and the myostatin/activin decoy taldefgrobep alfa - all trying to make GLP-1 weight loss 'higher quality' by protecting muscle.
The COURAGE trial and its 26-week numbers
COURAGE (NCT06299098) is a large randomized, double-blind Phase 2 study of about 999 participants. It tests trevogrumab - alone or paired with garetosmab, an antibody against activin A (a separate muscle-atrophy signal) - added to semaglutide, across two consecutive 26-week periods for weight loss and then weight maintenance. In the complete 26-week results, presented as a late-breaking oral session at EASD in September 2025, semaglutide alone cut lean body mass by about 6.5% from baseline. Adding trevogrumab roughly halved that: lean-mass loss fell to about 3.3% with the 200 mg dose and 3.8% with 400 mg. Put another way, of the ~33% of semaglutide weight loss that came from muscle, trevogrumab prevented about half.
The triplet: more fat off, more muscle kept
The most striking arm combined all three agents - semaglutide plus trevogrumab plus garetosmab. That triplet produced the greatest total weight loss, about 13.4% at 26 weeks, while limiting the fraction of weight lost as lean mass to roughly 7.4%. Blocking activin A on top of myostatin did double duty: adding garetosmab enhanced fat-mass reduction by about 27.3% over semaglutide alone while preserving more than 80% of lean body mass. In other words, the more of the muscle-wasting machinery the researchers blocked, the more the weight lost shifted toward fat - a clean demonstration that myostatin and activin A each contribute to the muscle loss seen with GLP-1 therapy.
The tolerability trade-off
More biology blocked also meant more side effects. Discontinuations due to adverse events were 4.6% with semaglutide alone and essentially unchanged at 4.7% when trevogrumab 200 mg was added - but rose to 10.6% at the 400 mg dose, and the garetosmab-containing arms carried a heavier side-effect burden overall. That is the central tension for this whole class: the combinations that protect the most muscle are also the ones most likely to cause problems, so the eventual winners will be decided as much by tolerability and durability as by peak body-composition numbers. Longer-term effects of chronic myostatin blockade on strength, function, and safety remain to be established.
Where it fits, and what to watch
Trevogrumab's pitch is not weight loss on its own - it is quality of weight loss layered onto a GLP-1 backbone. That places it in direct thematic competition with apitegromab, which posted its own lean-mass-sparing data alongside tirzepatide in the EMBRAZE trial, as well as bimagrumab and taldefgrobep alfa. The near-term questions are practical: full peer-reviewed COURAGE data, the durability of muscle preservation through the maintenance phase, and whether the muscle kept actually translates into measurable strength and function rather than just DXA numbers. COURAGE is expected to complete in late 2026, which should sharpen the picture. For now, trevogrumab is investigational, not approved for any use, and nothing here is medical advice.
Ready to track your peptide research?
Open PepTracker ProPepTracker Pro Research Team
The PepTracker Pro Research Team is an editorial group of science writers, pharmacologists, and clinical researchers dedicated to making peptide science accessible. Every article is reviewed for accuracy against peer-reviewed sources and updated as new evidence emerges.
Citations
- [1] Results from Phase 2 COURAGE Trial Demonstrating Potential to Improve Quality of GLP-1 Receptor Agonist-induced Weight Loss by Preserving Lean Mass, Presented at EASD - Regeneron (September 2025) Source
- [2] Regeneron Phase 2b Study Shows Antibodies Help Preserve Lean Mass During Weight Loss with Semaglutide - Patient Care Online (2025) Source
- [3] Myostatin Blocker Preserves Muscle With GLP-1 Treatment - Medscape (2025) Source
- [4] Regeneron's Semaglutide Plus Trevogrumab Combo Demonstrates Superior Fat Loss with Reduced Muscle Wasting in Obesity Trial - Pharmaceutical Executive (2025) Source
Related Articles
Apitegromab (SRK-015): The First Muscle-Targeted Myostatin Antibody to Win a Phase 3 - in SMA, and Now Obesity (July 14, 2026)
For two decades, drugging myostatin - the body's brake on muscle growth - was a graveyard of failed trials. Apitegromab changed that. Scholar Rock's antibody binds only the inactive precursor forms of myostatin, and in the Phase 3 SAPPHIRE trial it became the first muscle-targeted therapy to improve motor function in spinal muscular atrophy on top of SMN drugs. Now the same mechanism is showing up in obesity: in Phase 2 EMBRAZE, apitegromab preserved ~55% more lean mass during tirzepatide weight loss. Here is how it works, what the data show, and where its September 30, 2026 FDA decision stands.
CX11: Corxel's Oral Small-Molecule GLP-1 Posts 11.5% Weight Loss - and a Surprisingly Low Vomiting Rate (July 15, 2026)
Corxel's once-daily oral GLP-1 pill CX11 hit its Phase 2 endpoints with up to 11.5% weight loss at 36 weeks - and stood out most for what it didn't do: a vomiting rate of just 12-16% and no hepatic safety signal across 1,500+ participants. Here is where it fits in the crowded oral GLP-1 race.
WVE-007: Silencing a Fat-Storage Gene to Lose Fat Without Losing Muscle (July 29, 2026)
Most obesity drugs work on appetite. WVE-007 goes after the fat cell itself - it's a single-shot siRNA that silences INHBE, the liver gene behind the hepatokine Activin E, to release the brake on fat burning. In Wave's Phase 1 INLIGHT trial one dose cut visceral fat while lean mass held or rose, hinting at muscle-sparing weight loss and once- or twice-yearly dosing.